Skip to navigation Skip to content

Clinical Trial: Ozanimod to Improve Cognitive Function

Share

Details
Type of MS: RRMS|SPMS
Number of Subjects: 250
Medication: ozanimod (Zeposia®, Bristol Myers Squibb)
Location: Alabama|California|Colorado|District of Columbia|Florida|Georgia|Illinois|Indiana|Iowa|Kansas|Louisiana|Michigan|Minnesota|Missouri|Montana|New Jersey|New York|North Dakota|Ohio|Pennsylvania|Tennessee|Texas|Virginia|Washington|West Virginia|Wisconsin
Institutions: Multicenter, nationwide Contact Information
1-888-260-1599
clinicaltrialdisclosure@celgene.com

Funding:

Celgene

Description

 Investigators are recruiting 250 people with relapsing forms of MS for a clinical trial to determine if ozanimod (Zeposia®, Bristol Myers Squibb) improves cognitive functions, specifically information processing speed. The study is funded by Celgene.

Read more

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.